US 12,350,263 B2
Dosing and effect of C5a antagonist with ANCA-associated vasculitis
Jun Deng, Cupertino, CA (US); Petrus Bekker, Los Altos, CA (US); and Jan Hillson, Seattle, WA (US)
Assigned to CHEMOCENTRYX, INC., Thousand Oaks, CA (US)
Filed by CHEMOCENTRYX, INC., San Carlos, CA (US)
Filed on Nov. 4, 2021, as Appl. No. 17/519,266.
Application 17/519,266 is a continuation of application No. 16/433,487, filed on Jun. 6, 2019, granted, now 11,191,756.
Claims priority of provisional application 62/682,013, filed on Jun. 7, 2018.
Prior Publication US 2022/0296576 A1, Sep. 22, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/445 (2006.01); A61K 9/00 (2006.01); A61K 31/52 (2006.01); A61K 31/675 (2006.01); C07K 16/28 (2006.01); A61K 31/573 (2006.01)
CPC A61K 31/445 (2013.01) [A61K 9/0053 (2013.01); A61K 31/573 (2013.01); A61K 31/675 (2013.01); C07K 16/2887 (2013.01)] 24 Claims
 
1. A method of treating ANCA-associated vasculitis in a human having a reduced ability to fight infections, the method comprising administering to the human a therapeutically effective amount of avacopan:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof,
such that the level of plasma complement factor C5b-9 and C5a does not significantly change in the human upon treatment.